PRFX Share Price Performance
Recent PRFX News & Updates
No updates
PainReform Ltd. Key Details
Last Reported Earnings
Dec 31, 2024
Next Reporting Earnings
n/a
- Earnings per share (EPS)
- -7.25
- Gross Margin
- 0%
- Net Profit Margin
- 0%
- Debt/Equity Ratio
- 0%
PainReform Ltd. Competitors
About PRFX
- Founded
- 2007
- Employees
- 4
- CEO
- WebsiteView website
PainReform Ltd., a clinical stage specialty pharmaceutical company, focuses on the reformulation of established therapeutics and provides an extended period of post-surgical pain relief in Israel. It develops PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia, as well as in Phase 3 clinical trial for pain treatment of patients undergoing bunionectomy and pain treatment of hernia repair operations. The company was incorporated in 2007 and is based in Tel Aviv, Israel.
Israeli Market Performance
- 7 Days: -1.5%
- 3 Months: 21.3%
- 1 Year: 66.8%
- Year to Date: 28.8%
Over the last 7 days, the market has dropped 1.5%, driven by a decline of 1.9% in the Financials sector. As for the longer term, the market has actually risen by 67% in the last year. As for the next few years, earnings are expected to grow by 16% per annum. Market details ›
This week, we’re diving deeper into the world of agentic AI. We’re zeroing in on the core technologies that make these intelligent agents actually reliably work. We explore what all this could mean for software, start-ups, and most importantly, the opportunities and risks each industry faces by adopting Agentic AI.
Continue reading